Hyperosmolar hyperglycemic syndrome induced by diazoxide and furosemide in a 5-year-old girl

Haruka Nakazawa¹, Yuki Naruse¹, Masato Mori¹, and Ryugo Hiramoto¹
¹The Department of Pediatrics, Matsudo City General Hospital Centre, Children’s Medical Centre, Matsudo, Japan

Abstract. Hyperglycemia and hyperosmolar hyperglycemic syndrome (HHS) are the rare adverse effects of diazoxide. Furosemide has been reported to worsen glucose tolerance and cause HHS. A 5-yr-old girl presented to the emergency department with complaints of tachycardia, polyuria, and lethargy for 1 wk prior to hospitalization. She was treated with two diuretics for aortic valve reflux disease and diazoxide for congenital hyperinsulinemia. She was diagnosed with HHS based on her serum glucose level of 529 mg/dL and serum osmotic pressure of 357 mOsm/kg. There were no findings suggestive of new-onset diabetes mellitus. She had fever on admission and was diagnosed with a urinary tract infection. The blood diazoxide level at the time of hospitalization was 25 µg/dL. Diazoxide use, even in patients with low diazoxide levels, may cause hyperglycemia. Patients on diuretics and diazoxide must be carefully monitored, considering the risk of developing HHS.

Key words: Hyperosmolar hyperglycemic syndrome, diazoxide, furosemide, congenital hyperinsulinemia

Introduction

Hyperosmolar hyperglycemic syndrome (HHS) can lead to serious hyperglycemia due to relative insulin deficiency and increased secretion of counterregulatory hormones, such as glucagon, catecholamine, and growth hormone, as well as severe dehydration and electrolyte abnormalities (hyperosmolarity) due to osmotic diuresis (1). Although HHS is rare in children, it has a high mortality rate and requires intensive care unit treatment (1). Diazoxide treatment for hyperinsulinemia can lead to the onset of hyperglycemia or HHS as a serious adverse effect (3–6). We herein report a case of HHS induced by concomitant use of diazoxide and diuretics, despite a low blood diazoxide level.

Case Presentation

A 5-yr-old girl with Cornelia de Lange syndrome was treated with diazoxide therapy (5 mg/kg per d) for congenital hyperinsulininemia (CHI). She was also taking furosemide (1 mg/kg per d) and spironolactone (1 mg/kg per d) for the aortic bicuspid valve and aortic regurgitation. She was on prophylactic antibiotics because she had grade 3 left vesicoureteral reflux disease. She also underwent tracheostomy and brachiocephalic artery transection for laryngomalacia and tracheomalacia. She had no family history of diabetes mellitus. She started taking enalapril maleic acid (0.1 mg/kg per d) after consultation with a cardiovascular outpatient clinic 2 wk before hospitalization.

She experienced tachycardia and polyuria 1 wk prior to hospitalization. She had a fever (body temperature, 37.7°C) a day before hospitalization. Her blood test showed a C-reactive protein of 9.8 mg/dL; hence, she was administered tosufloxacin. On the day of hospitalization, she was lethargic and admitted to the pediatric intensive care unit. Blood investigations revealed hyperglycemia and hypernatremia.

Case Report
hypernatremia associated with intravascular dehydration, with a blood glucose level of 529 mg/dL and serum osmotic pressure of 357 mOsm/kg (Table 1). Based on the above findings, the patient was diagnosed with HHS. Intensive investigation was continued during treatment to determine the etiology.

Pulse rate (140 beats/min) and consciousness level (GCS, E4VT5) improved after the peripheral venous route was secured and intravenous extracellular fluid (20 mL/kg) was administered. Diazoxide was stopped, and fluid infusion was continued at a rate of 8 mL/kg/h. Her blood glucose level improved to 185 mg/dL 3 h after hospitalization. The infusion was changed to a maintenance fluid with a glucose level of 9.6% (glucose infusion rate, 6.8 mg/kg/min). The blood glucose and electrolyte levels were corrected. Insulin was not administered because of coexisting hyperinsulinemia and rapid improvement of blood glucose levels with fluid replacement alone.

Blood investigations revealed an increased inflammatory response (white blood cell count, 12,900/µL; C-reactive protein, 9.62 mg/dL) along with an infection (Table 1). The patient had a history of artificial bloodstream infection, and urinary tract infection. She was then administered cefepime. Chest X-ray was normal. Her blood amylase, lipase, and creatinine kinase levels were normal. Anti-GAD, IA2, and anti-insulin antibodies were negative. The HbA1c was 5.8%, and the blood C-peptide level was 5.13 mg/dL. Escherichia coli was detected in urine culture. She was diagnosed with breakthrough urinary tract infection because a single bacterial species was detected during the antibacterial therapy. She was treated with sulfamethoxazole and trimethoprim based on the susceptibility results, and a prophylactic dose was administered.

Chest and abdominal CT scans conducted on the third day of hospitalization did not show any abscess or inflammatory changes in the artificial blood vessel, and no deep abscess was detected. There were improvements, as indicated by a serum osmotic pressure of 291 mOsm/kg, serum sodium level of 143 mEq/L, and blood glucose level of 105 mg/dL on day 7 of hospitalization. Blood investigations revealed an increased inflammatory response (white blood cell count, 12,900/µL; C-reactive protein, 9.62 mg/dL) along with an infection (Table 1). The patient had a history of artificial bloodstream infection, and urinary tract infection. She was then administered cefepime. Chest X-ray was normal. Her blood amylase, lipase, and creatinine kinase levels were normal. Anti-GAD, IA2, and anti-insulin antibodies were negative. The HbA1c was 5.8%, and the blood C-peptide level was 5.13 mg/dL. Escherichia coli was detected in urine culture. She was diagnosed with breakthrough urinary tract infection because a single bacterial species was detected during the antibacterial therapy. She was treated with sulfamethoxazole and trimethoprim based on the susceptibility results, and a prophylactic dose was administered.

Table 1. Laboratory data on admission

| CBC | Atrial blood gas | Urine test |
|-----|------------------|------------|
| WBC 12900 /µL | pH 7.413 | Protein (2+) |
| Hb 12.6 mg/dL | pCO₂ 51 mmHg | Ketone (-) |
| Hct 42.8 % | HCO₃⁻ 31.9 mEq/L | Occult blood (2+) |
| Plt 28.1 x 10 /µL | BE 6 mEq/L | Urobilinogen (+) |
|                 | Lac 1.5 mmol/L | Bilirubin (-) |
|                 | Na 157.7 mEq/L | WBC 30–49/HPF |
|                 | K 4.33 mEq/L | RBC 10–19/HPF |
|                 | Cl 122 mEq/L |                |
|                 | AG 8 mmol/L |                |

| Biochemical test | Culture |
|------------------|---------|
| TP 6.7 g/dL | Plasma glucose 529 mg/dL | Urine culture E. coli 10¹⁴ |
| Alb 3.6 g/dL | HbA1c (NGSP) 5.8 % | Sputum culture negative |
| AST 109 IU/L | 3-hydroxyacetic acid 0.1 µmol/L | Blood culture negative |
| ALT 142 IU/L | Insulin 11.6 µU/mL | Serum concentration diazoxide 25 µg/mL |
| LDH 330 IU/L | C-peptide 5.13 ng/mL | |
| T-Bil 0.15 mg/dL | ACTH 38 pg/mL | |
| CK 11 IU/L | IGF1 8 ng/mL | |
| BUN 41.3 mg/dL | Plasma cortisol 32.8 µg/dL | |
| Cre 0.39 mg/dL | GH 0.7 mg/mL | |
| Na 160 mEq/L | TSH 3.011 µIU/mL | |
| K 4.5 mEq/L | fT3 2.24 ng/mL | |
| Cl 120 mEq/L | fT4 0.66 ng/dL | |
| Ca 9.2 mEq/L | Anti IA2 antibody < 0.6 U/mL | |
| P 2.9 mEq/L | Anti GAD antibody < 5.0 U/mL | |
| Tchol 190 mg/dL | Anti insulin antibody < 0.4 U/mL | |
| TG 321 mg/dL | Serum osmolarity 357 osm/kg | |
| CRP 9.56 mg/dL | Serum concentration | |
| Lipase 23 mg/dL | | |
| Amylase 33 U/L | | |
glucose monitoring using the Dexcom G4 Platinum CGM system (San Diego, CA) revealed repeated hypoglycemic episodes at night and before meals. We considered the possibility that the patient’s hyperglycemia was caused by unnecessary diazoxide medication. A controlled fast test and glucagon load test were conducted on day 9 of hospitalization, and the patient was again diagnosed with hyperinsulinemic hypoglycemia (Table 2). Diazoxide was resumed on the same day at the same dose as that before hospitalization (5 mg/kg per d). She was discharged from the hospital on day 20 of hospitalization after we confirmed that she did not show hypoglycemia after consuming cornstarch, and all diuretics were discontinued. Her HbA1c and plasma blood glucose levels were within the normal range after discharge from the hospital, and she had no hyperglycemic episodes with diazoxide.

**Discussion**

HHS has a reported mortality rate of 10–20% in adults and a poor prognosis (1). It is rare among children, but most cases are associated with new-onset type 1 diabetes or uncontrolled type 2 diabetes mellitus. Recently, more cases have been reported with an increase in the frequency of type 2 diabetes (1–3). Reports have indicated that the risk factors for HHS include complications of pneumonia and urinary tract infections, cerebrovascular accidents, drugs, peritoneal dialysis, burns, and dehydration (1, 3). HHS is also caused by severe hyperglycemia due to the administration of glucocorticoids, excessive diuretics, and atypical antipsyhotics (1). In our patient, the blood glucose level did not reach > 600 mg/dL, as defined by the ISPAD Clinical Practice Consensus Guidelines 2018 (2). Although there was no metabolic acidosis or ketosis, hyperglycemia and hyperosmolarity were observed. Based on these clinical findings, HHS was diagnosed.

The development of new-onset diabetes mellitus in our patient was eliminated based on various antibody titers, HbA1c levels, and blood C-reactive protein levels at the time of hospitalization. Diazoxide-related adverse effects were initially suspected.

Several case reports have reported that HHS develops during the administration of diazoxide for hyperinsulinemia or insulinoma (3–6). A report indicated that the risk of diabetes or hyperglycemia increases when the blood diazoxide level is > 100 µg/dL (7). However, in our patient, the diazoxide level was only 25 µg/dL. Diazoxide is a renally excreted drug with a T1/2 of 15 ± 5.3 h, and steady-state serum concentrations are known to correlate with the dose of diazoxide (dose/kg per d).

Pharmacokinetic simulations have shown that there is no significant difference in steady-state serum concentrations between twice daily and three times daily divided doses, as long as the total daily dose is equivalent.

Previous reports have shown that once-daily administration or a higher daily dose of diazoxide than the recommended dose can result in higher serum levels.
concentrations. The initial dose of diazoxide for pediatric patients (< 1 yr of age) with hyperinsulinemia is 5–10 mg/kg per d divided into three times a day up to a maximum of 15 mg/kg per d (7, 8). In this case, the patients were continuously taking diazoxide (5 mg/kg per d, twice a day); thus, we considered her serum concentration to be stable. In fact, her serum concentration of diazoxide after oral administration for 6 h was not high.

We believe that the pathophysiology of HHS in this case is not absolute insulin deficiency due to diabetes mellitus, but infection, diuresis, and relative insulin deficiency.

First, urinary tract infection causes overproduction of counterregulatory hormones, which leads to impaired glucose utilization and accelerated glycogenesis. This was followed by osmotic diuresis and dehydration. Next, the increase in hypotonic urine by furosemide worsened dehydration and hyperosmolality. In addition, a previous animal study showed that furosemide may worsen glucose intolerance and cause HHS (9). Finally, diazoxide suppressed insulin secretion, resulting in impaired glucose utilization.

The CHI guidelines recommend thiazide diuretics over loop diuretics; however, as noted above, diuretics can exacerbate hyperglycemia and hyperosmolality. Diuretics should be used cautiously in patients with CHI taking diazoxide (10).

Conclusion

In conclusion, regular blood glucose monitoring should be performed, and patients should be carefully monitored for hypoglycemia and hyperglycemia during diazoxide treatment. In addition, furosemide administration must be carefully considered during diazoxide treatment.

Acknowledgements

We express our deep gratitude to Dr. Yamagishi and Dr. Inokuchi, as well as the members of the Chiba University Education and Research Center of Legal Medicine, for estimating the blood diazoxide levels.

References

1. Karslioglu French E, Donihi AC, Korytkowski MT. Diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome: review of acute decompensated diabetes in adult patients. BMJ 2019;365:11114. [Medline] [CrossRef]
2. Wolfsdorf JJ, Glaser N, Agus M, Fritsch M, Hanas R, Rewers A, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr Diabetes 2018;19(Suppl 27): 155–77. [Medline] [CrossRef]
3. Reddy A, Finley L, Horrall S. Hyperosmolar hyperglycemic syndrome in a young boy. Proc Bayl Univ Med Cent 2019;32: 627–8. [Medline] [CrossRef]
4. Mangla P, Hussain K, Ellard S, Flanagan SE, Bhatia V. Diazoxide toxicity in a child with persistent hyperinsulinemic hypoglycemia of infancy: mixed hyperglycemic hyperosmolar coma and ketoacidosis. J Pediatr Endocrinol Metab 2018;31: 943–5. [Medline] [CrossRef]
5. Savage JM, Slattery C. Hyperosmolar non-ketotic hyperglycaemia during oral diazoxide therapy of prolonged hyperglycaemia in infancy. Ulster Med J 1977;46: 123–6. [Medline]
6. Balsam MJ, Baker L, Kaye R. Hyperosmolar nonketotic coma associated with diazoxide therapy for hypoglycemia. J Pediatr 1971;78: 523–5. [Medline] [CrossRef]
7. Kizu R, Nishimura K, Sato R, Kosaki K, Tanaka T, Tanigawara Y, et al. Population pharmacokinetics of diazoxide in children with hyperinsulinemic hypoglycaemia. Horm Res Paediatr 2017;88: 316–23. [Medline] [CrossRef]
8. Demirbilek H, Hussain K, Demirbilek H, Hussain K. Congenital hyperinsulinism: Diagnosis and treatment update. J Clin Res Pediatr Endocrinol 2017;9(Suppl 2): 69–87. [Medline]
9. Foy JM, Furman BL. Effect of single dose administration of diuretics on the blood sugar of alloxan-diabetic mice or mice made hyperglycaemic by the acute administration of diazoxide. Br J Pharmacol 1973;47: 124–32. [Medline] [CrossRef]
10. Yorifuji T, Horikawa R, Hasagawa T, Adachi M, Soneda S, Minagawa M, et al. (on behalf of The Japanese Society for Pediatric Endocrinology and The Japanese Society of Pediatric Surgeons). Clinical practice guidelines for congenital hyperinsulinism. Clin Pediatr Endocrinol 2017;26: 127–52. [Medline] [CrossRef]